EU Funding Initiative Targets Next-Generation Malaria Vaccines for Global Health
The European Union is actively funding research and innovation through its Horizon Europe program to accelerate the development of next-generation vaccines against Plasmodium vivax malaria. This initiative, detailed on the EU Funding & Tenders Portal, highlights the severity of P. vivax, which affects 2.5 billion people across South America, Oceania, and Asia. The program, specifically under the topic HORIZON-HLTH-2022-DISEASE-06-03-two-stage, aims to achieve a 75% vaccine efficacy over two years, aligning with the revised Malaria Vaccine Technology Roadmap to 2030. Key participants include STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM from the Netherlands, serving as the coordinator, and INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE from France. The project, named OptiViVax, will integrate multidisciplinary scientific and clinical approaches, leveraging recent breakthroughs in P. vivax vaccine research, including new transgenic parasite technologies and a safe parasite clone for controlled hu...